COVID-19大流行对全球抗菌药物耐药性监测、预防与控制的影响:一项全球调查
结果显示67%的国家与AMR伙伴合作能力受限,中低收入国家资金和试剂/耗材减少更显著(P<0.01),护理、医疗和公共卫生人员减少分别报告为71%、69%和64%。
要点
- COVID-19期间67%国家AMR伙伴合作能力受限,中低收入国家资金减少更显著。
- 护理、医疗和公共卫生人员减少分别报告为71%、69%和64%。
- 58%报告试剂/耗材减少,中低收入国家更显著(P<0.01)。
核心结论
- 这是首个探索COVID-19对GLASS国家AMR全球影响的调查,强调需确保AMR仍是全球卫生优先事项。
主要发现
- 67%报告与AMR伙伴合作能力受限,中低收入国家资金减少频繁报告(P<0.01)。
- 护理、医疗和公共卫生人员减少分别报告为71%、69%和64%,67%报告清洁人员可用性稳定。
- 58%报告试剂/耗材减少,中低收入国家更显著(P<0.01)。
- 培养、择期手术、慢性病住院和门诊数量减少及ICU入院增加可能使AMR数据产生偏倚。
- 总体感染预防与控制(IPC)改善可能降低AMR率,但部分不适当IPC实践和抗菌药物处方增加可能升高AMR率。
临床怎么用
- 应参与GLASS以促进可靠的AMR监测数据。
- 利用机会发展更可持续的IPC规划。
- 推广整合的抗菌药物管理指导,利用增强的实验室能力及其他系统强化措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The COVID-19 pandemic has had a substantial impact on health systems. The WHO Antimicrobial Resistance (AMR) Surveillance and Quality Assessment Collaborating Centres Network conducted a survey to assess the effects of COVID-19 on AMR surveillance, prevention and control. METHODS: From October to December 2020, WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) national focal points completed a questionnaire, including Likert scales and open-ended questions. Data were descriptively analysed, income/regional differences were assessed and free-text questions were thematically analysed. RESULTS: Seventy-three countries across income levels participated. During the COVID-19 pandemic, 67% reported limited ability to work with AMR partnerships; decreases in funding were frequently reported by low- and middle-income countries (LMICs; P < 0.01). Reduced availability of nursing, medical and public health staff for AMR was reported by 71%, 69% and 64%, respectively, whereas 67% reported stable cleaning staff availability. The majority (58%) reported reduced reagents/consumables, particularly LMICs (P < 0.01). Decreased numbers of cultures, elective procedures, chronically ill admissions and outpatients and increased ICU admissions reported could bias AMR data. Reported overall infection prevention and control (IPC) improvement could decrease AMR rates, whereas increases in selected inappropriate IPC practices and antimicrobial prescribing could increase rates. Most did not yet have complete data on changing AMR rates due to COVID-19. CONCLUSIONS: This was the first survey to explore the global impact of COVID-19 on AMR among GLASS countries. Responses highlight important actions to help ensure that AMR remains a global health priority, including engaging with GLASS to facilitate reliable AMR surveillance data, seizing the opportunity to develop more sustainable IPC programmes, promoting integrated antibiotic stewardship guidance, leveraging increased laboratory capabilities and other system-strengthening efforts.
引用
- Tomczyk S, Taylor A, Brown A, et al. Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey. J Antimicrob Chemother. 2021. PMID: 34473285. doi:10.1093/jac/dkab300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。